EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options

Jérôme Martineau iD, Solange N Walz iD, Matteo Scampa iD, Salvatore Giordano iD, Daniel F Kalbermatten iD, Carlo M Oranges iD

Journal of Clinical Medicine · 04.03.2023 · 12 (5) · 2045

DOI: 10.3390/jcm12052045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 04.03.2023. Verfasst von Jérôme Martineau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Spiradenocarcinoma is an extremely rare malignant adnexal tumor and there are only few studies on survival outcomes. Our aim was to perform an analysis of the demographic and pathological characteristics, treatment patterns, and survival outcomes of patients affected by spiradenocarcinoma. (2)

Methods

The Surveillance, Epidemiology, and End Results program database of the National Cancer Institute was searched for all cases of spiradenocarcinoma diagnosed between 2000 and 2019. This database is considered representative of the US population. Demographic, pathological, and treatment variables were retrieved. Overall and disease-specific survival were computed according to the different variables. (3)

Results

90 cases of spiradenocarcinoma (47 females, 43 males) were identified. Mean age at diagnosis was 62.8 years. Regional and distant disease at diagnosis were rare, occurring in 2.2% and 3.3% of cases, respectively. Surgery alone was the most frequent treatment (87.8%), followed by a combination of surgery and radiotherapy (3.3%) and radiation therapy only (1.1%). Five-year overall survival was 76.2% and five-year disease-specific survival was 95.7%. (4)

Conclusions

Spiradenocarcinoma equally affects males and females. Regional and distant invasion rates are low. Disease-specific mortality is low and is probably overestimated in the literature. Surgical excision remains the main form of treatment.

Schlagwörter

Stichwörter der Autor:innen

SEERadnexal tumoreccrineepidemiologymalignantskinspiradenocarcinomaspiradenomasurvivaltreatment

Autor:innen und Institutionen

  • Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.
  • Department of General and Plastic Surgery, Turku University Hospital, University of Turku, 20014 Turku, Finland.

ORCID-Profile: Jérôme Martineau, Solange N Walz, Matteo Scampa, Salvatore Giordano, Daniel F Kalbermatten, Carlo M Oranges

Zitieren

APA

Martineau, J., Walz, S. N., Scampa, M., Giordano, S., Kalbermatten, D. F., & Oranges, C. M. (2023). Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options. Journal of Clinical Medicine, 12(5), 2045. https://doi.org/10.3390/jcm12052045

Vancouver

Martineau J, Walz SN, Scampa M, Giordano S, Kalbermatten DF, Oranges CM. Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options. Journal of Clinical Medicine. 2023;12(5):2045. doi:10.3390/jcm12052045

BibTeX
@article{Martineau2023,
  author = {Martineau, Jérôme and Walz, Solange N and Scampa, Matteo and Giordano, Salvatore and Kalbermatten, Daniel F and Oranges, Carlo M},
  title = {Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {5},
  pages = {2045},
  doi = {10.3390/jcm12052045}
}
Kostenlos starten →